These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1706612)

  • 1. The cell membrane and cell signals: new targets for novel anticancer drugs.
    Workman P
    Ann Oncol; 1990; 1(2):100-11. PubMed ID: 1706612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways.
    Powis G
    Semin Cancer Biol; 1992 Dec; 3(6):343-50. PubMed ID: 1286155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signalling targets for anticancer drug development.
    Powis G
    Trends Pharmacol Sci; 1991 May; 12(5):188-94. PubMed ID: 1862534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth factor and oncogene signalling pathways as targets for rational anticancer drug development.
    Powis G; Kozikowski A
    Clin Biochem; 1991 Oct; 24(5):385-97. PubMed ID: 1760877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of phospholipid intracellular signaling as antiproliferative agents.
    Powis G; Hill SR; Frew TJ; Sherrill KW
    Med Res Rev; 1995 Mar; 15(2):121-38. PubMed ID: 7739293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-genomic actions of aldosterone: from receptors and signals to membrane targets.
    Dooley R; Harvey BJ; Thomas W
    Mol Cell Endocrinol; 2012 Mar; 350(2):223-34. PubMed ID: 21801805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.
    Raymond E; Faivre S; Armand JP
    Drugs; 2000; 60 Suppl 1():15-23; discussion 41-2. PubMed ID: 11129168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of target of rapamycin inhibitors.
    Easton JB; Houghton PJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
    Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
    Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of anticancer drugs that act against signalling pathways.
    Powis G
    Tumori; 1994 Apr; 80(2):69-87. PubMed ID: 8016910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.
    Denekamp J
    Br J Radiol; 1993 Mar; 66(783):181-96. PubMed ID: 7682469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cephalostatin analogues--synthesis and biological activity.
    Flessner T; Jautelat R; Scholz U; Winterfeldt E
    Fortschr Chem Org Naturst; 2004; 87():1-80. PubMed ID: 15079895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy.
    Arcangeli A; Crociani O; Lastraioli E; Masi A; Pillozzi S; Becchetti A
    Curr Med Chem; 2009; 16(1):66-93. PubMed ID: 19149563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salinomycin and its derivatives - A new class of multiple-targeted "magic bullets".
    Antoszczak M; Huczyński A
    Eur J Med Chem; 2019 Aug; 176():208-227. PubMed ID: 31103901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.